BRAF and cancer: This finding of a similar extent of mutation of this important tumour suppressor gene in BRAF mutant/MSS and BRAF wild-type cancers was the first report of molecular similarity occurring between the serrated and conventional pathways and provided evidence of a molecular overlap between the two.